CoChat

DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen

Open access
Franc, Sylvia, Hanaire, Hélène, Benhamou, Pierre-Yves, Schaepelynck, Pauline, Catargi, Bogdan, Farret, Anne, Fontaine, Pierre, Guerci, Bruno, Reznik, Yves, Jeandidier, Nathalie, Penfornis, Alfred, Borot, Sophie, Chaillous, Lucy, Serusclat, Pierre, Kherbachi, Yacine, d'Orsay, Geneviève, Detournay, Bruno, Simon, Pierre, Charpentier, Guillaume · 2020 · Diabetes Technology & Therapeutics
Cited by 38

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: The DIABEO ® system (DS) is a telemedicine solution that combines a mobile app for patients with a web portal for health care providers. DS allows real-time monitoring of basal-bolus insulin therapy as well as therapeutic decision-making, integrating both basal and bolus dose calculation. Real-life studies have shown a very low rate of use of mobile health applications by patients. Therefore, we conducted a large randomized controlled trial study to investigate the efficacy of DS in conditions close to real life (TELESAGE study). Methods: TELESAGE was a multicenter, randomized, open study with three parallel arms: arm 1 (standard care), arm 2 (DIABEO alone), and arm 3 (DIABEO+telemonitoring by trained nurses). The primary outcome assessed the reduction in HbA 1c levels after a 12-month follow-up. Results: Six hundred sixty-five patients were included in the study. Participants who used DIABEO once or more times a day (DIABEO users) showed a significant and meaningful reduction of HbA 1c versus standard care after a 12-month follow-up: mean difference −0.41% for arm 2—arm 1 ( P = 0.001) and −0.51% for arm 3—arm 1 ( P ≤ 0.001). DIABEO users included 25.1% of participants in arm 2 and 37.6% in arm 3. In the intention-to-treat population, HbA 1c changes and incidence of hypoglycemia were comparable between arms. Conclusions: A clinical and statistically significant reduction in HbA 1c levels was found in those patients who used DIABEO at least once a day.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2020.0021

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 38

Metadata

Authors
Franc, S., Hanaire, H., Benhamou, P.-Y., Schaepelynck, P., Catargi, B., Farret, A., Fontaine, P., Guerci, B., Reznik, Y., Jeandidier, N., Penfornis, A., Borot, S., Chaillous, L., Serusclat, P., Kherbachi, Y., d'Orsay, G., Detournay, B., Simon, P., & Charpentier, G.
Venue
Diabetes Technology & Therapeutics
Published
2020-12-01
Volume
22
Issue
12
Pages
904-911
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W3025999980
Cited by
38
References
6
FWCI
4.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen. https://app.cochat.ai/papers/10.1089/dia.2020.0021
The paper
Franc, S., Hanaire, H., Benhamou, P.-Y., Schaepelynck, P., Catargi, B., Farret, A., Fontaine, P., Guerci, B., Reznik, Y., Jeandidier, N., Penfornis, A., Borot, S., Chaillous, L., Serusclat, P., Kherbachi, Y., d'Orsay, G., Detournay, B., Simon, P., & Charpentier, G. (2020). DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2020.0021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.